Additional inclusion of phosphaturic activity of the fibroblast growth factor (FGF-23) and the determination of its coreceptor (Klotho protein) in RRMS patients would have had an impact on the conclusions [20]. This evidence concerns the gene FGF23 and relapsing-remitting multiple sclerosis.